Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14194734 | 0.85 | GSK3B (0.57) | GSK3BPPARGPDE9AKDM4EALDH1A1 | |
| SCHEMBL1918027 | 0.84 | GSK3B (0.66) | GSK3BCCNE1CDK2 | |
| SCHEMBL6890465 | 0.84 | GSK3B (0.46) | GSK3BPPARGALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL6895081 | 0.83 | GSK3B (0.64) | GSK3BCCNE1CDK2 | |
| SCHEMBL6886976 | 0.82 | KDM4E (0.48) | GSK3BPPARGKDM4EALDH1A1HPGD | |
| SCHEMBL6890102 | 0.81 | CSNK2A1 (0.52) | GSK3BPPARGKDM4EALDH1A1HPGD | |
| SCHEMBL14194730 | 0.80 | GSK3B (0.48) | GSK3BPPARGCDK2 | |
| SCHEMBL6891061 | 0.80 | GSK3B (0.46) | GSK3BPPARGPDE9AHSD17B10CCNE1 | |
| SCHEMBL6886202 | 0.78 | CDK2 (0.52) | GSK3BPPARGKDM4EALDH1A1CCNE1 | |
| SCHEMBL6889269 | 0.77 | CDK2 (0.46) | GSK3BPPARGCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | claimed |
| EP-1345941-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-24 | — | — | EP | claimed |
| WO-2002050079-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | claimed |
| EP-1438039-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-21 | — | — | EP | disclosed |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-15 | — | — | US | disclosed |
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | disclosed |
| EP-1345941-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002096348-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002050079-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | CDK1, CDK3, CDKL3 | GSK3B 25/4885PPARG 249/4885PDE9A 3129/4885 |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | DTYMK, DGKG, DGKZ | GSK3B 2441/4885PPARG 2873/4885PDE9A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.